Proteon Therapeutics (PRTO) Given Daily Coverage Optimism Score of 0.17
News stories about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteon Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.1148126592562 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Proteon Therapeutics (NASDAQ PRTO) remained flat at $$1.90 during trading on Tuesday. The company’s stock had a trading volume of 36,400 shares, compared to its average volume of 109,594. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $10.57.
A number of analysts have weighed in on PRTO shares. Zacks Investment Research cut Proteon Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 11th. Robert W. Baird reiterated a “hold” rating and issued a $2.00 price target on shares of Proteon Therapeutics in a research report on Friday, November 10th. HC Wainwright reiterated a “hold” rating and issued a $2.30 price target on shares of Proteon Therapeutics in a research report on Wednesday, November 8th. Oppenheimer reiterated a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Finally, Cowen reiterated a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. Proteon Therapeutics has a consensus rating of “Hold” and an average target price of $3.16.
In other Proteon Therapeutics news, Director James E. Flynn acquired 110,557 shares of Proteon Therapeutics stock in a transaction on Thursday, November 30th. The shares were bought at an average price of $1.75 per share, with a total value of $193,474.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 36.30% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/05/proteon-therapeutics-prto-given-daily-coverage-optimism-score-of-0-17.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.